DavidLSultzerMD
Psychiatry • Orange, CAGeriatric Psychiatry, Neuropsychiatry, Pain Medicine
Professor of Psychiatry and Human Behavior, and Director, Clinical Research, Institute for Memory Impairments and Neurological Disorders, UC Irvine School of Medicine
Dr. Sultzer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
UC Irvine
Psychiatry
Orange, CA 92868
Education & Training
UCLA/Stewart & Lynda Resnick Neuropsychiatric HospitalFellowship, Neurobehavior, 1988 - 1990- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Psychiatry, 1983 - 1987
University of North Carolina at Chapel Hill School of MedicineClass of 1983
Certifications & Licensure
CA State Medical License 1984 - 2026- American Board of Psychiatry and Neurology Psychiatry
- American Board of Psychiatry and Neurology Geriatric Psychiatry
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
Clinical Trials
- Curcumin and Yoga Therapy for Those at Risk for Alzheimer's Disease Start of enrollment: 2014 Jan 20
- Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo Start of enrollment: 2013 Jul 01
Publications & Presentations
PubMed
- 363 citationsEfficacy and Comparative Effectiveness of Atypical Antipsychotic Medications for Off-Label Uses in Adults: A Systematic Review and Meta-AnalysisAlicia Ruelaz Maher, Margaret Maglione, Steven C. Bagley, Marika J. Suttorp, Jian Hui Hu
JAMA. 2011-09-28 - 100 citationsRelapse Risk after Discontinuation of Risperidone in Alzheimer's DiseaseDevangere P. Devanand, Jacobo Mintzer, Susan K. Schultz, Howard Andrews, David L. Sultzer
The New England Journal of Medicine. 2012-10-17 - 188 citationsClinical Symptom Responses to Atypical Antipsychotic Medications in Alzheimer’s Disease: Phase 1 Outcomes from the CATIE-AD Effectiveness TrialDavid L. Sultzer, Sonia M. Davis, Pierre N. Tariot, Karen S. Dagerman, Barry D. Lebowitz
The American Journal of Psychiatry. 2008-07-01
Authored Content
- Sertraline for the Treatment of Depression in Vascular Cognitive ImpairmentApril 2018
- Sertraline for the Treatment of Depression in Vascular Cognitive ImpairmentApril 2018
- Domain Score Is Associated with Lower MetabolicJuly 2017
Press Mentions
Futuristic Vaccine to Prevent Alzheimer’s Starts Southern California TrialMarch 2nd, 2023- UCI MIND Awarded $14.4MM NIH Grant to Continue Critical Research and EducationJuly 13th, 2020
- UC Irvine Awarded $14.4 Million Alzheimer’s Research GrantJuly 10th, 2020
- Join now to see all
Grant Support
- Cholinergic Receptors In Aging And Alzheimers Disease Ligand NeuroimagingVeterans Affairs2011
- Delusions And Cerebral Metabolism In Alzheimers DiseaseNational Institute Of Mental Health1997–2001
- Psychiatric Symptoms In Alzheimers DiseaseNational Institute Of Mental Health1994–1995
- Psychiatric &Behavioral Disturbances In Alzheimer'S DISNational Institute Of Mental Health1991–1993
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
